Delivery Order SPE2DB22D1106-SPE2DB25FFGJ3
- Not listed
- The Defense Logistics Agency awarded a $29,419.28 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Enbrel 50 mg/ml syringes. The contract, which carries an ultimate completion date of August 8, 2025, represents a non-set-aside, competitively awarded procurement with performance fulfilled at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $37,120.42 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. The contract is a firm fixed price delivery order with an ultimate completion date of August 20, 2025, and represents a non-set-aside competitive award. AmerisourceBergen's corporate office, located in Conshohocken, Pennsylvania, will serve as the place of performance. This delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,738.89 to AmerisourceBergen Drug Corp for the supply of ENBREL 50 mg/mL syringes. This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award carries no set-aside designation, reflecting open competition among eligible vendors. This...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Enbrel 50 mg/mL syringes, valued at $9,158.68 with a firm fixed price structure. The contract has an ultimate completion date of August 15, 2025, and will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This is a non-set-aside competitive award issued as a child delivery order under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $9,168.81 to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes, with an ultimate completion date of July 31, 2025. This firm fixed-price delivery order was competitively awarded without set-aside designation to AmerisourceBergen's Corporate Office located in Conshohocken, Pennsylvania. The contract represents a continuation of pharmaceutical supply delivery under AmerisourceBergen's broader federal contracting...
- The Defense Logistics Agency (DLA) awarded a $23,699.92 delivery order to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/mL syringes, with an ultimate completion date of August 19, 2025. This is a firm fixed price, non-set-aside contract awarded competitively on August 18, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $9,158.68 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Enbrel 50 mg/ml syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 21, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a near-term pharmaceutical supply requirement within the military healthcare supply chain. This award is issued under...
- The Defense Logistics Agency awarded a $5,504.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for Enbrel 50 mg/ml syringes, with an ultimate completion date of August 19, 2025. This non-set-aside contract represents a direct award to the pharmaceutical distributor, which maintains its corporate office in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.999...
- The Defense Logistics Agency awarded a $58,286.34 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Enbrel 50 mg/mL syringes. The contract employs firm fixed pricing with no set-aside designation and is scheduled for completion by August 5, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform work at its corporate office location. This delivery order represents a child contract issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency Medical Supply Chain awarded a delivery order valued at $34,598.52 to AmerisourceBergen Drug Corp for the supply of Enbrel Surclk 50mg in quantities of four units. This firm fixed-price delivery order, issued on August 4, 2025, with an ultimate completion date of August 29, 2025, was competitively awarded with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FFGJ3Delivery Order
The Defense Logistics Agency awarded a delivery order valued at $70,857.49 to AmerisourceBergen Drug Corp for the supply of Enbrel 50 mg/ml syringes. This firm fixed price, competitively awarded contract was executed on September 2, 2025, with an ultimate completion date of September 3, 2025, and will be performed at the contractor's corporate office in Conshohocken, Pennsylvania. The delivery order carries no set-aside designation, reflecting the open competitive procurement process through which it was awarded. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical procurement vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceuticals and medical supplies to support military and veteran healthcare systems. The Enbrel delivery represents part of the company's ongoing commitment to fulfilling specialized pharmaceutical requirements across the Defense Health Agency and broader federal healthcare networks.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $70.9k | 9/2/25 |